ReviewFrontiers in tuberculosis2024
The role of the immune response in developing tuberculosis infection: from latent infection to active tuberculosis.
Review in Frontiers in tuberculosis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Fractal-fractional model for analysis of tuberculosis infection using Ethiopia incidence data.Quantitative biology (Beijing, China) · 2026Article
- The epidemiology of tuberculosis infection and the Human Development Index (HDI) in Iran between 1990-2021: secondary analysis of the global burden of disease.BMC infectious diseases · 2026Article
- Detection for New Biomarkers of Tuberculosis Infection Activity Using Machine Learning Methods.Diseases (Basel, Switzerland) · 2026Review
- Forkhead box O3 transcription factor fine-tunes IL-6 expression in mycobacteria-infected macrophages.Frontiers in immunology · 2026Article
- Detection of latent tuberculosis infection in healthcare workers.Frontiers in medicine · 2026Article
- Differential regulation of monocyte oxidative burst by isoniazid in healthy and latent tuberculosis-infected subjects.Frontiers in pharmacology · 2026Article
- Tuberculosis incidence in patients treated with secukinumab - a real-world study in Brazil.Advances in rheumatology (London, England) · 2025Article
- Alterations in the Immune Response in Individuals with Latent Tuberculosis Infection.Pathogens (Basel, Switzerland) · 2025Review
- A predictive model for evaluating the risk of latent tuberculosis relapse via machine learning.BMC infectious diseases · 2025Article
- Article
- Immunological testing and machine learning in detecting latent tuberculosis among high-risk groups (nature review).Frontiers in medicine · 2025Review
- Investigation of the prevalence of latent tuberculosis in cancer patients compared to non-cancer patients: a case-control study.Oncology reviews · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite advancements in modern medicine, tuberculosis continues to be one of the leading causes of death globally. Findings indicate that COVID-19 may trigger the activation of tuberculosis infection (TB), leading to its spread. Despite the development of new immunological diagnostic methods for latent tuberculosis infection (LTBI), it is still unclear how the infection transitions to an active TB state. The goal of the study is to provide insights into the progression of tuberculosis infection from a latent to an active state. This article presents recent research data focused on investigating the pathogenesis of LTBI, particularly the immune responses in the interaction between
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.